These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34219146)

  • 21. Improving pathology and laboratory medicine in low-income and middle-income countries: roadmap to solutions.
    Sayed S; Cherniak W; Lawler M; Tan SY; El Sadr W; Wolf N; Silkensen S; Brand N; Looi LM; Pai SA; Wilson ML; Milner D; Flanigan J; Fleming KA
    Lancet; 2018 May; 391(10133):1939-1952. PubMed ID: 29550027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Untangling the corruption maze: exploring the complexity of corruption in the health sector.
    Sommersguter-Reichmann M; Reichmann G
    Health Econ Rev; 2024 Jul; 14(1):50. PubMed ID: 38995456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of corruption in the health sector: theory, methods and interventions.
    Vian T
    Health Policy Plan; 2008 Mar; 23(2):83-94. PubMed ID: 18281310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. We Need to Talk About Corruption in Health Systems.
    Hutchinson E; Balabanova D; McKee M
    Int J Health Policy Manag; 2019 Apr; 8(4):191-194. PubMed ID: 31050963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Where Do We Start? Building Consensus on Drivers of Health Sector Corruption in Nigeria and Ways to Address It.
    Onwujekwe O; Orjiakor CT; Hutchinson E; McKee M; Agwu P; Mbachu C; Ogbozor P; Obi U; Odii A; Ichoku H; Balabanova D
    Int J Health Policy Manag; 2020 Jul; 9(7):286-296. PubMed ID: 32613800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Corruption in global health: the open secret.
    García PJ
    Lancet; 2019 Dec; 394(10214):2119-2124. PubMed ID: 31785827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. For a honest Maghreb care system. Systematic Review of the International Literature on Corruption in the Health care System.
    Kacem M; Melki S; Nouira S; Khelil M; Sriha Belguith A; Ben Abdelaziz A
    Tunis Med; 2019 Mar; 97(3):397-406. PubMed ID: 31729714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Corruption risks in relations between doctor and patient ].
    Kolwitz M; Gąsiorowski J
    Ann Acad Med Stetin; 2014; 60(1):134-9. PubMed ID: 25518104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-corruption, Transparency and Accountability: Case Study of Healthcare in the Arab Countries.
    Hunter M; Uwaydah Mardini R; El-Seblani A; Elsayed S
    Glob Health Action; 2020; 13(sup1):1704529. PubMed ID: 32194015
    [No Abstract]   [Full Text] [Related]  

  • 30. Factors affecting the informal payments in public and teaching hospitals.
    Aboutorabi A; Ghiasipour M; Rezapour A; Pourreza A; Sarabi Asiabar A; Tanoomand A
    Med J Islam Repub Iran; 2016; 30():315. PubMed ID: 27390685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting anticorruption interventions at the front line: developmental governance in health systems.
    Hutchinson E; Naher N; Roy P; McKee M; Mayhew SH; Ahmed SM; Balabanova D
    BMJ Glob Health; 2020 Dec; 5(12):. PubMed ID: 33272939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies for Fighting Medicare Fraud.
    McGee J; Sandridge L; Treadway C; Vance K; Coustasse A
    Health Care Manag (Frederick); 2018; 37(2):147-154. PubMed ID: 29697574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Narrative Synthesis Review of Out-of-Pocket Payments for Health Services Under Insurance Regimes: A Policy Implementation Gap Hindering Universal Health Coverage in Sub-Saharan Africa.
    Derkyi-Kwarteng ANC; Agyepong IA; Enyimayew N; Gilson L
    Int J Health Policy Manag; 2021 Jul; 10(7):443-461. PubMed ID: 34060270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tackling corruption in the pharmaceutical systems worldwide with courage and conviction.
    Cohen JC; Mrazek M; Hawkins L
    Clin Pharmacol Ther; 2007 Mar; 81(3):445-9. PubMed ID: 17251983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kickbacks, courtesies or cost-effectiveness?: Application of the Medicare antikickback Law to the marketing and promotional practices of drug and medical device manufacturers.
    Bulleit TN; Krause JH
    Food Drug Law J; 1999; 54(3):279-323. PubMed ID: 11797701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health care fraud and abuse laws.
    Klein RD; Campbell S
    Arch Pathol Lab Med; 2006 Aug; 130(8):1169-77. PubMed ID: 16879018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Corruption in healthcare: a view from the pandemic.
    Duliba Y; Streltsov Y; Kharchenko V; Korchak N; Antonova O
    Med Leg J; 2024 Mar; 92(1):43-45. PubMed ID: 36510470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Good veterinary governance: definition, measurement and challenges.
    Msellati L; Commault J; Dehove A
    Rev Sci Tech; 2012 Aug; 31(2):413-30. PubMed ID: 23413724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paying for performance to improve the delivery of health interventions in low- and middle-income countries.
    Diaconu K; Falconer J; Verbel A; Fretheim A; Witter S
    Cochrane Database Syst Rev; 2021 May; 5(5):CD007899. PubMed ID: 33951190
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.